tiprankstipranks
Trending News
More News >
ZimVie Inc (ZIMV)
NASDAQ:ZIMV
Advertisement

ZimVie Inc (ZIMV) AI Stock Analysis

Compare
56 Followers

Top Page

ZIMV

ZimVie Inc

(NASDAQ:ZIMV)

Rating:67Neutral
Price Target:
$20.50
▲(8.07% Upside)
ZimVie's overall stock score reflects a mix of challenges and opportunities. The acquisition by ARCHIMED at a premium is a major positive factor, providing potential future stability and growth. However, ongoing financial performance issues, such as declining revenue and profitability challenges, weigh down the score. Technical indicators show bullish momentum, but caution is advised due to overbought signals. Valuation remains a concern due to negative earnings.
Positive Factors
Acquisition
ZIMV announced an agreement to be acquired by ARCHIMED for an enterprise value of $730M, translating to $19 per share.
Financial Performance
ZIMV beat consensus revenue and EPS in 2Q25.
Market Outlook
Guidance provided during the conference suggests a favorable outlook for the company's performance.
Negative Factors
Pricing
Pricing was a headwind, primarily driven by domestic implants.
Product Performance
Implants and scanners were the two weakest product groups in the quarter.
Revenue Miss
ZIMV missed consensus revenue while adjusted EBITDA met expectations in 4Q24.

ZimVie Inc (ZIMV) vs. SPDR S&P 500 ETF (SPY)

ZimVie Inc Business Overview & Revenue Model

Company DescriptionZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
How the Company Makes MoneyZimVie Inc makes money by selling its medical technology products and solutions primarily in the dental and spine markets. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics, where it offers a range of products such as dental implants, biomaterials, and digital dentistry solutions. Additionally, ZimVie generates income through the sale of spinal fusion and fixation devices, which are used by surgeons and healthcare facilities in various spinal surgeries. The company may also benefit from strategic partnerships and collaborations that expand its market reach and product offerings, contributing to its overall earnings.

ZimVie Inc Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q1-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
ZimVie reported strong profitability and margin improvements, driven by strategic focus on high-margin products and operational efficiencies. However, revenue declined due to market challenges and lower international sales. The positive financial outcomes and strategic moves suggest a positive outlook, but revenue headwinds balance the sentiment.
Q1-2025 Updates
Positive Updates
Improved Profitability and Margin Expansion
Achieved $17 million of adjusted EBITDA with a 15.7% margin, an improvement of over 500 basis points from the previous year, despite a challenging market environment.
Successful Launch of Immediate Molar Implant System
The immediate molar implant system exceeded internal growth expectations, contributing to unit sales growth in March and April.
Digital Dentistry Growth
ZimVie digital solutions, excluding scanner sales, grew in high single digits with the implant concierge service growing 11% year-over-year.
Strategic Acquisition in Costa Rica
Acquired a distributor partner in Costa Rica, enhancing the company's direct sales presence and improving margin profile.
Cost Reduction and Efficiency Improvements
Achieved a reduction of 350 basis points in adjusted total cost of products sold, contributing to improved profitability.
Successful Portfolio Strategy
Focus on proprietary implant sales and development over low-margin products, leading to a favorable product mix.
Negative Updates
Revenue Decline
Net sales decreased by 5.2% in reported rates and declined by 4.1% in constant currency compared to the prior year.
International Sales Challenges
Outside the U.S., net sales decreased 8.5% on a reported basis due to lower implant sales and other headwinds, despite some normalization.
Continued Softness in Implant Sales
Implant sales declined in low single digits due to ongoing macroeconomic pressures, consistent with the broader market.
Company Guidance
During ZimVie's First Quarter 2025 Earnings Conference Call, CEO Vafa Jamali highlighted several key metrics reflecting the company's financial performance and strategic initiatives. ZimVie reported total revenue of $112 million and achieved an adjusted EBITDA margin of 15.7%, marking a 500-basis point improvement from the previous year. The company generated over $17 million in adjusted EBITDA, representing a 40% year-over-year increase, despite facing a challenging market environment. A significant reduction of over 350 basis points in adjusted total cost of products sold contributed to these results. ZimVie maintained its full-year revenue guidance of $445 million to $460 million and an adjusted EBITDA range of $65 million to $70 million. The company also successfully launched its immediate molar implant system, which exceeded internal growth expectations, and saw a high single-digit growth in its digital dentistry business. Despite a decrease in net sales by 5.2% and a 4.1% decline in constant currency, the company focused on advancing its commercial strategy and streamlining its operations to drive profitability and shareholder value.

ZimVie Inc Financial Statement Overview

Summary
ZimVie Inc. faces ongoing challenges with revenue declines and profitability issues. Despite some improvement in cash flow and equity ratio, high leverage and negative margins present risks. The company needs to focus on improving operational efficiencies and revenue growth to enhance financial health.
Income Statement
45
Neutral
ZimVie Inc. has struggled with declining revenues, from $1,014.6 million in 2021 to $443.6 million in TTM. The net profit margin is negative, indicating ongoing losses, though there is a slight improvement in EBITDA margin in TTM. This reflects challenges in maintaining both revenue levels and profitability.
Balance Sheet
55
Neutral
The debt-to-equity ratio is relatively high at approximately 0.59 in TTM, indicating significant leverage. However, the equity ratio has improved to 52.97%, showing moderate financial stability. The company’s ROE remains negative, suggesting inefficiencies in generating returns on equity.
Cash Flow
60
Neutral
The company has managed a positive free cash flow in TTM, although it has decreased from previous periods. Operating cash flow to net income ratio is not favorable due to negative net income, but cash flow management shows some resilience.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue443.40M449.75M457.43M913.86M1.01B912.40M
Gross Profit289.57M287.45M290.38M613.08M628.80M599.50M
EBITDA42.90M29.61M91.07M79.16M28.70M-86.70M
Net Income-19.47M-25.82M-393.28M-63.88M-95.30M-179.00M
Balance Sheet
Total Assets758.22M753.67M1.21B1.64B1.83B1.95B
Cash, Cash Equivalents and Short-Term Investments70.18M74.97M71.51M89.60M100.40M27.40M
Total Debt234.54M232.57M521.93M564.14M57.90M89.20M
Total Liabilities345.42M371.97M795.85M883.45M375.30M458.70M
Stockholders Equity412.80M381.71M409.49M758.60M1.45B1.49B
Cash Flow
Free Cash Flow5.62M7.49M24.66M-1.92M7.70M47.70M
Operating Cash Flow11.97M14.17M37.15M24.63M64.30M86.00M
Investing Cash Flow-12.78M282.30M-15.17M-28.66M-60.30M-49.50M
Financing Cash Flow-18.70M-294.67M-25.67M-1.31M72.30M-46.50M

ZimVie Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.97
Price Trends
50DMA
14.78
Positive
100DMA
11.93
Positive
200DMA
12.63
Positive
Market Momentum
MACD
1.00
Positive
RSI
81.24
Negative
STOCH
62.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIMV, the sentiment is Positive. The current price of 18.97 is above the 20-day moving average (MA) of 18.88, above the 50-day MA of 14.78, and above the 200-day MA of 12.63, indicating a bullish trend. The MACD of 1.00 indicates Positive momentum. The RSI at 81.24 is Negative, neither overbought nor oversold. The STOCH value of 62.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZIMV.

ZimVie Inc Risk Analysis

ZimVie Inc disclosed 39 risk factors in its most recent earnings report. ZimVie Inc reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ZimVie Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$24.48B37.679.73%0.93%2.47%63.68%
76
Outperform
$23.36B101.7519.18%25.99%-40.46%
74
Outperform
$21.30B26.136.52%0.90%4.11%-14.43%
67
Neutral
$534.97M-4.76%-19.52%94.65%
61
Neutral
$3.09B30.62-17.87%8.57%-1154.64%
54
Neutral
$573.06M-24.63%4.84%0.85%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZIMV
ZimVie Inc
18.90
1.70
9.88%
PODD
Insulet
337.60
132.45
64.56%
OFIX
Orthofix
14.74
-2.63
-15.14%
STE
Steris
248.98
13.62
5.79%
ZBH
Zimmer Biomet Holdings
105.06
-8.56
-7.53%
LIVN
LivaNova
55.45
5.21
10.37%

ZimVie Inc Corporate Events

Delistings and Listing ChangesM&A Transactions
ZimVie Inc to be Acquired by ARCHIMED
Positive
Jul 21, 2025

On July 21, 2025, ZimVie Inc. announced a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share in cash, valuing the company at approximately $730 million. The transaction, which represents a 99% premium over ZimVie’s 90-day volume-weighted average price, is expected to close by the end of 2025, pending customary closing conditions and stockholder approval. The merger agreement includes a ‘Go-Shop’ period allowing ZimVie to solicit alternative acquisition proposals until August 29, 2025. Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ.

The most recent analyst rating on (ZIMV) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

Executive/Board ChangesShareholder Meetings
ZimVie Inc Holds Annual Shareholders Meeting
Neutral
May 13, 2025

ZimVie Inc. held its annual shareholders meeting on May 7, 2025, where key decisions were made regarding company governance and executive compensation. Shareholders elected a Class III director, ratified PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan on a non-binding advisory basis.

The most recent analyst rating on (ZIMV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
ZimVie Inc Reports Q1 2025 Financial Results
Negative
May 8, 2025

On May 8, 2025, ZimVie Inc. reported its financial results for the first quarter of 2025, showing net sales of $112.0 million, which marked a 5.2% decrease compared to the same period in 2024. Despite a net loss of $2.6 million, the company improved its net loss margin significantly from the previous year. Adjusted EBITDA increased to $17.6 million, reflecting a 15.7% margin. The company remains focused on operational efficiency and profitability improvements, aiming for a return to top-line growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025